文献速递类风湿关节炎

COBRA早期类风湿关节炎试验队列23年随访死亡率与普通人群相当

Normal mortality of the COBRA early rheumatoid arthritis trial cohort after 23 years of follow-up.
PubMed 文献 · Ann Rheum Dis · 2019-02-26

COBRA试验将早期类风湿关节炎患者随机分配至柳氮磺吡啶单药治疗或COBRA联合方案(柳氮磺吡啶+低剂量甲氨蝶呤+初始高剂量泼尼松龙逐步减量),随访23年比较全因死亡率与荷兰普通人群参考样本。结果显示44例患者死亡(28%,SMR=0.80 [95%CI 0.59-1.06]),与普通人群死亡率相似,支持早期强化治疗的长期获益。

要点

  • 早期RA强化治疗23年后死亡率与普通人群相当(SMR=0.80 [95%CI 0.59-1.06])。
  • COBRA联合治疗组与SSZ单药组死亡率无显著差异(p=0.61)。
  • 28周时损伤进展、高HAQ评分及HLA-DR2/3缺失与死亡风险增加相关。

核心结论

  • 这项早期RA前瞻性试验队列研究是首批显示23年随访后死亡率与普通人群相似的研究之一。
  • 结果证实早期强化治疗RA具有长期获益,并提示达标治疗对预后不良患者尤为重要。

研究设计与样本

  • COBRA试验将早期RA患者随机分配至柳氮磺吡啶单药治疗(SSZ,n=79)或SSZ+低剂量甲氨蝶呤+初始高剂量泼尼松龙逐步减量联合治疗(COBRA,n=76)。
  • 随访至2017年,与荷兰普通人群参考样本比较死亡率(标准化死亡比,SMR),并通过逐步Cox回归分析早期预后因素与死亡率的关系。

主要发现

  • 存活患者平均随访23年(范围22-24年),共44例患者死亡(28%,SMR=0.80 [95%CI 0.59-1.06])。
  • COBRA组75例中20例死亡(27%,SMR=0.75 [95%CI 0.47-1.14]),SSZ组79例中24例死亡(30%,SMR=0.85 [95%CI 0.56-1.25]),组间p=0.61。
  • 普通人群参考样本中55例死亡(36%)。
  • 与死亡风险增加显著相关的5个因素包括:28周时损伤进展;高HAQ评分及HLA-DR2或3缺失;从症状开始计算的病程亦显著但模式难以解释。

关键数值与推荐

  • 全队列SMR=0.80(95%CI 0.59-1.06),COBRA组SMR=0.75(95%CI 0.47-1.14),SSZ组SMR=0.85(95%CI 0.56-1.25),组间比较p=0.61。

临床怎么用

  • 对早期RA患者应积极采用早期强化治疗策略,以追求长期获益。
  • 对存在28周损伤进展、高HAQ评分或HLA-DR2/3缺失等预后不良因素的患者,尤应重视达标治疗。

局限性

  • 原文未报告局限性相关内容。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: Mortality in patients with rheumatoid arthritis (RA) is higher than in the general population. We investigated mortality in the COBRA-trial cohort after 23 years follow-up, compared with a reference sample of the Dutch population. METHODS: The COBRA-trial randomised patients with early RA to sulfasalazine monotherapy (SSZ, n=79) or a combination of SSZ, low-dose methotrexate and initially high, step-down prednisolone (COBRA, n=76). We compared the mortality in the COBRA-trial up to 2017 to a reference sample of the general population in the Netherlands (standardised mortality ratio, SMR), and its relation to early prognostic factors through stepwise Cox regression. RESULTS: Duration of follow-up in patients alive was mean 23 (range 22-24) years. In total, 44 patients died (28%, SMR=0.80 [95% CI 0.59 to 1.06]); 20 of 75 COBRA patients (27%, SMR 0.75 [0.47 to 1.14]) and 24 of 79 SSZ patients (30%, SMR 0.85 [0.56 to 1.25]); p=0.61). In the reference sample of the general population, 55 people (36%) died. 5 factors were significantly associated with increased mortality hazard: damage progression at 28 weeks; high Health Assessment Questionnaire (HAQ) score and absence of HLA-DR 2 or 3; disease duration from start of complaints was also significant, but showed an uninterpretable pattern. CONCLUSIONS: This prospective trial cohort study of early RA is one of the first to show similar mortality compared with the general population after 23 years of follow-up. It confirms that early, intensive treatment of RA has long-term benefits and suggests that treating to target is especially important for patients with poor prognosis.

来源:Ann Rheum Dis,查看原文。版权归原作者所有。

引用

  1. Poppelaars PBM, van Tuyl LHD, Boers M, et al. Normal mortality of the COBRA early rheumatoid arthritis trial cohort after 23 years of follow-up. Ann Rheum Dis. 2019. PMID: 30808623. doi:10.1136/annrheumdis-2018-214618

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。